What we are studying
This research study is a way of gaining new knowledge about GBM. If you decide to take part, you will be known as a “participant” rather than a “patient”. This research study is evaluating an investigational drug called VB-111 as a possible treatment for GBM. “Investigational” means that the drug VB-111 is still being studied and that research doctors are trying to find out more about it. It also means that the FDA (U.S. Food and Drug Administration) has not approved VB-111 for use in patients, including people with your type of cancer.
It is expected that approximately 252 people will take part in this study; half will receive VB-111 together with bevacizumab and half will receive bevacizumab alone. Bevacizumab is currently approved by the FDA for treatment of recurrent GBM. It is anticipated that approximately 8 subjects will participate at this site.
Subjects will be reimbursed for mileage